Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives
Rebecca Liu,1 Kyle Staller1,2 1Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; 2Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USACorrespondence: Kyle StallerMassachusett...
Saved in:
Main Authors: | Liu R (Author), Staller K (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2020-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
by: Özdener AE, et al.
Published: (2017) -
Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
by: Sobolewska-Włodarczyk A, et al.
Published: (2016) -
Eluxadoline Versus Antispasmodics in the Treatment of Irritable Bowel Syndrome: An Adjusted Indirect Treatment Comparison Meta-analysis
by: Di Qin, et al.
Published: (2022) -
Eluxadoline-Loaded Eudragit Nanoparticles for Irritable Bowel Syndrome with Diarrhea: Formulation, Optimization Using Box-Behnken Design, and Anti-Diarrheal Activity
by: Md. Khalid Anwer, et al.
Published: (2023) -
Preparation, Evaluation and Bioavailability Studies of Eudragit Coated PLGA Nanoparticles for Sustained Release of Eluxadoline for the Treatment of Irritable Bowel Syndrome
by: Md. K. Anwer, et al.
Published: (2017)